Global Summits Confront Cell & Gene Therapy Scale-Up: Automation, Cost Efficiency, and Mass Production Strategies

August 30, 2026

Informa Connect International

Overview

Upcoming international conferences, including Advanced Therapies Europe and the CAR-TCR Summit in September 2026, are set to address the urgent need for scalable and cost-effective manufacturing in cell and gene therapy. Discussions will center on overcoming production challenges such as ensuring product consistency, optimizing COGs, managing complex supply chains, and navigating diverse regulatory landscapes. A key focus will be on leveraging closed systems, automation, and advanced analytics to enable efficient, high-volume production and accelerate global patient access to these life-saving treatments.

In Depth

Background

Cell and gene therapies represent groundbreaking therapeutic options for previously untreatable diseases. However, their widespread commercialization has been significantly hampered by persistent manufacturing bottlenecks. Key impediments to broader adoption include prohibitively high production costs, limited manufacturing capacity, inherent product variability, and an increasingly complex and disparate global regulatory landscape. Recognizing the critical need for a collaborative approach, the industry is increasingly leveraging international conferences as vital platforms for knowledge sharing, exchanging best practices, and establishing harmonized industry standards.

Key Findings

In September 2026, several prominent international conferences, including Advanced Therapies Europe, the CAR-TCR Summit, and the Cell & Gene Therapy World Conference, will intensively address the most critical manufacturing challenges facing cell and gene therapies. These global events are designed to deliver actionable strategies and illustrative case studies focused on ensuring robust product consistency, optimizing the Cost of Goods Sold (COGs), surmounting complex supply chain hurdles, and navigating stringent regulatory requirements across jurisdictions. A significant emphasis will be placed on the practical implementation of closed systems, advanced automation technologies, and innovative analytical approaches. These advancements are crucial for driving highly efficient and scalable manufacturing processes, ultimately accelerating global access to these transformative therapies.

Manufacturing & Regulatory Innovations

Process Optimization and Automation: Current cell and gene therapy manufacturing is often plagued by manual processes and inherent high variability. Conference discussions will illuminate advanced approaches to optimize workflows from initial cell culture to final product formulation. This includes integrating automated closed systems—critical for minimizing human error, enhancing reproducibility, and significantly increasing throughput for both autologous (patient-specific) and allogeneic (off-the-shelf) therapies.
Quality Control and Analytics: Implementing robust quality control (QC) strategies and leveraging advanced analytical technologies are paramount for ensuring the safety, potency, and overall quality of sophisticated cell and gene therapy products. Key topics will include real-time monitoring systems, sophisticated in-process controls, and innovative quality assessment tools, all vital for maintaining product consistency and achieving stringent regulatory compliance.
Supply Chain Efficiency: The supply chain for cell and gene therapies presents unique and exceptional complexities. This spans from the meticulous sourcing of specialized raw materials, such as living cells and viral vectors, to the precise transport and storage of highly sensitive final products. Conference sessions will delve into strategies for optimized cold chain management, advanced logistics, and comprehensive risk mitigation, all aimed at reducing costs and bolstering overall supply stability and reliability.
Regulatory Compliance and Accelerated Approval: The novel and intricate nature of cell and gene therapy modalities necessitates strict adherence to diverse and evolving regulatory requirements across various international jurisdictions. These conferences will foster critical dialogues on optimal strategies for accelerating the approval process and provide crucial insights into data submission requirements, often featuring direct engagement with leading regulatory bodies such as the FDA, EMA, and Japan’s PMDA.

Strategic Outlook

The convergence of advanced manufacturing technologies and intensified international collaborative efforts is poised to dramatically transform the landscape of cell and gene therapy manufacturing in the coming years. It is widely anticipated that closed and automated systems, alongside AI-driven quality control mechanisms, will transition from innovative concepts to industry standards. This evolution will unlock significantly more efficient and cost-competitive production workflows. Ultimately, these advancements are expected to vastly expand patient access to these life-saving therapies and catalyze substantial further growth within the global cell and gene therapy market. The collective insights and best practices shared at these pivotal conferences will serve as a crucial driving force in making next-generation therapeutic innovations globally accessible.

Source: https://informaconnect.com/cell-therapy-bioprocessing/cell-therapy-manufacturing-analytics-cell-gene-therapy-international/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.